The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Purpose: To count patients with newly diagnosed epilepsy entering early and late remission and to identify prognostic predictors of late remission.
Methods: Children and adults with previously untreated epilepsy from two Italian tertiary centers (Monza, Bari) were the study population. All patients received monotherapy at treatment start; drug choice and schedule were left to the physician’s judgment...
Prognosis describes the trajectory and long‐term outcome of a condition. Most studies indicate a better prognosis in idiopathic generalized epilepsy (IGE) in comparison with other epilepsy syndromes. Studies looking at the long‐term outcome of different IGE syndromes are relatively scant. Childhood absence epilepsy appears to have a higher rate of remission compared to juvenile absence epilepsy. In...
The incidence, prevalence, and mortality of epilepsy vary across countries with different economies. Differences can be explained by methodological problems, premature mortality, seizure remission, socioeconomic factors, and stigma. Diagnostic misclassification—one possible explanation—may result from inclusion of patients with acute symptomatic or isolated unprovoked seizures. Other sources of bias...
ObjectivesThe burden of epilepsy, in terms of both morbidity and mortality, is likely to vary depending on the etiology (primary [genetic/unknown] vs. secondary [structural/metabolic]) and with the use of antiepileptic drugs (AEDs). We estimated the disability‐adjusted life years (DALYs) and modeled the remission rates of active convulsive epilepsy (ACE) using epidemiologic data collected over the...
ObjectivesDetermine frequency of remissions, relapses, and pharmacoresistance over two decades. Develop a composite measure of seizure control over that time.
MethodsCommunity‐based cohort of children with newly diagnosed epilepsy prospectively followed for up to 21 years with frequent calls and periodic medical record review. Multiple periods of 1‐, 2‐, 3‐, and 5‐year remission with subsequent relapses...
Objective
To explore the influence of several estimates of family socioeconomic status on the long‐term clinical course and social outcomes of children with epilepsy.
Methods
The Nova Scotia childhood epilepsy cohort is population based and includes all children in this Canadian province who developed epilepsy between 1977 and 1985. Eligible patients had ≥10 years of follow‐up. Children with childhood...
Objective
We aimed to compare long‐term social outcomes in young adults with childhood‐onset epilepsy (cases) with neurologically normal sibling controls.
Methods
Long‐term social outcomes were assessed at the 15‐year follow‐up of the Connecticut Study of Epilepsy, a community‐based prospective cohort study of children with newly diagnosed epilepsy. Young adults with childhood‐onset epilepsy with...
Objectives
To establish the risk of subsequent intractable epilepsy after ≥2, ≥5, and ≥10 years of remission in childhood‐onset epilepsy.
Methods
From the Nova Scotia childhood‐onset epilepsy population‐based cohort patients with all types of epilepsy were selected with ≥20 years follow‐up from seizure onset (incidence cases). Children with childhood absence epilepsy were excluded. The rate of...
Objective
We aim to identify people with epilepsy who are unlikely to reachieve a 12‐month remission within 2 years after experiencing a breakthrough seizure following an initial 12‐month remission.
Methods
We apply a novel longitudinal discriminant approach to data from the Standard and New Antiepileptic Drugs study to dynamically predict the risk of a patient not achieving a second remission...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.